Login to Your Account



Other News To Note


Monday, April 18, 2011
Pozen Inc., of Chapel Hill, N.C., said the U.S. District Court for the Eastern District of Texas granted a preliminary injunction ordering Par Pharmaceutical Inc., of Woodcliff Lake, N.J., not to make, use, sell, offer to sell or import into the U.S. a generic version of Treximet (sumatriptan/naproxen sodium). Treximet is sold by Pozen's partner, London-based GlaxoSmithKline plc. The order was entered in connection with the patent infringement lawsuit pending among Pozen and a handful of generic firms.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription